{"id":8961,"date":"2022-03-22T15:30:37","date_gmt":"2022-03-22T14:30:37","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=8961"},"modified":"2022-03-22T15:30:37","modified_gmt":"2022-03-22T14:30:37","slug":"evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/","title":{"rendered":"Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers"},"content":{"rendered":"<p>Evommune, Inc., a clinical-stage biotechnology company dedicated to the development of transformative medicines for inflammatory diseases, today announced enrollment of the first participant in its Phase 1 study of EVO101 in healthy volunteers. EVO101 is a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) which broadly inhibits innate inflammation and is being developed as a treatment for inflammatory skin diseases.<\/p>\n<p>\u00ab\u00a0We are excited to enroll the first participant into a clinical study of EVO101, the first of several programs in our pipeline approaching clinical development,\u00a0\u00bb said\u00a0<span class=\"xn-person\">Eugene A. Bauer<\/span>, M.D., chief medical officer of Evommune. \u00ab\u00a0Given EVO101&rsquo;s potent inhibitory activity, this compound has the potential to be a first-in-class treatment with significant efficacy across a broad spectrum of patients. Based on the results of this study,\u00a0we expect to rapidly advance EVO101 into Phase 2a clinical trials in patients suffering from atopic dermatitis and rosacea.\u00a0\u00bb<\/p>\n<p>The open-label Phase 1 study will assess the safety and tolerability of EVO101 in healthy adult volunteers. Participants will apply EVO101 topical cream, 0.1% twice daily and be evaluated for adverse events and local skin responses over a 7-day period.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Evommune, Inc., a clinical-stage biotechnology company dedicated to the development of transformative medicines for inflammatory diseases, today announced enrollment of the first participant in its Phase 1 study of EVO101 in healthy volunteers. EVO101 is a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) which broadly inhibits innate inflammation and is being&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-8961","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Evommune, Inc., a clinical-stage biotechnology company dedicated to the development of transformative medicines for inflammatory diseases, today announced enrollment of the first participant in its Phase 1 study of EVO101 in healthy volunteers. EVO101 is a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) which broadly inhibits innate inflammation and is being...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-22T14:30:37+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers\",\"datePublished\":\"2022-03-22T14:30:37+00:00\",\"dateModified\":\"2022-03-22T14:30:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/\"},\"wordCount\":200,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/\",\"name\":\"Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2022-03-22T14:30:37+00:00\",\"dateModified\":\"2022-03-22T14:30:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/","og_locale":"fr_FR","og_type":"article","og_title":"Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers - ANDERA PARTNERS","og_description":"Evommune, Inc., a clinical-stage biotechnology company dedicated to the development of transformative medicines for inflammatory diseases, today announced enrollment of the first participant in its Phase 1 study of EVO101 in healthy volunteers. EVO101 is a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) which broadly inhibits innate inflammation and is being...","og_url":"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2022-03-22T14:30:37+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers","datePublished":"2022-03-22T14:30:37+00:00","dateModified":"2022-03-22T14:30:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/"},"wordCount":200,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/","url":"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/","name":"Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2022-03-22T14:30:37+00:00","dateModified":"2022-03-22T14:30:37+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/fr\/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/8961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=8961"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/8961\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=8961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=8961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}